Mylan NV (NASDAQ:MYL) Shares Sold by Fifth Third Bancorp
Fifth Third Bancorp lowered its position in shares of Mylan NV (NASDAQ:MYL) by 40.1% in the first quarter, HoldingsChannel.com reports. The firm owned 3,244 shares of the company’s stock after selling 2,173 shares during the quarter. Fifth Third Bancorp’s holdings in Mylan were worth $48,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Wealthcare Advisory Partners LLC grew its stake in shares of Mylan by 83.6% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 1,219 shares of the company’s stock worth $25,000 after purchasing an additional 555 shares in the last quarter. Samalin Investment Counsel LLC purchased a new stake in Mylan in the fourth quarter valued at $26,000. Acadian Asset Management LLC purchased a new stake in Mylan in the fourth quarter valued at $26,000. Huntington National Bank purchased a new stake in Mylan in the fourth quarter valued at $30,000. Finally, S.A. Mason LLC purchased a new stake in Mylan in the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 84.90% of the company’s stock.
A number of equities research analysts recently weighed in on MYL shares. Royal Bank of Canada reissued a “buy” rating and issued a $26.00 price target on shares of Mylan in a research report on Tuesday, May 12th. Wells Fargo & Co reduced their price target on shares of Mylan from $23.00 to $18.00 and set an “equal weight” rating for the company in a research report on Thursday, April 30th. SunTrust Banks reissued a “buy” rating and issued a $27.00 price target on shares of Mylan in a research report on Wednesday, February 5th. ValuEngine cut shares of Mylan from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 2nd. Finally, UBS Group boosted their price target on shares of Mylan from $16.00 to $17.00 and gave the company a “neutral” rating in a research report on Wednesday, May 13th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the stock. Mylan has a consensus rating of “Hold” and a consensus price target of $23.46.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.04. The firm had revenue of $2.62 billion during the quarter, compared to analysts’ expectations of $2.65 billion. Mylan had a net margin of 0.54% and a return on equity of 20.00%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.82 earnings per share. As a group, research analysts forecast that Mylan NV will post 4.34 EPS for the current fiscal year.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: How to trade on quiet period expirations
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.